Sugi Predict

Sugi Predict / Compounds / SCHEMBL617351

SCHEMBL617351

SCHEMBL617351

CC(C)(C)c1c(C(=O)NC2C3CC4CC(C3)CC2C4)cnn1-c1ccc(C(=O)O)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ HSD11B1 P28845 19/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26657984 1.00 HSD11B1 (1.00) HSD11B1
Water SCHEMBL618837 0.99 HSD11B1 (0.98) HSD11B1
SCHEMBL1192385 0.90 HSD11B1 (0.81) HSD11B1
SCHEMBL1402990 0.89 HSD11B1 (1.00) HSD11B1
SCHEMBL13688661 0.89 HSD11B1 (0.80) HSD11B1
SCHEMBL13260066 0.89 HSD11B1 (0.80) HSD11B1
SCHEMBL1402703 0.87 HSD11B1 (1.00) HSD11B1
SCHEMBL1402812 0.85 HSD11B1 (0.74) HSD11B1
SCHEMBL1402956 0.84 HSD11B1 (0.72) HSD11B1
SCHEMBL1402525 0.83 HSD11B1 (1.00) HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116549662-A Osteogenesis targeting molecule modified 11 beta-HSD 1 inhibitor conjugate, and preparation method and application thereof 北京和理咨询有限公司 2023-08-08 — — CN claimed
US-8344016-B2 Pyrazole derivatives as 11-beta-HSD1 inhibitors ASTRAZENECA AB (SE) 2013-01-01 — — US claimed
US-20120041211-A1 NOVEL PROCESS FOR PREPARING CARBOXY-CONTAINING PYRAZOLEAMIDO COMPOUNDS 597 ASTRAZENECA INDIA PRIVATE LIMITED (IN) 2012-02-16 — — US claimed
EP-2391607-A1 NOVEL PROCESS FOR PREPARING CARBOXY-CONTAINING PYRAZOLEAMIDO COMPOUNDS 597 AstraZeneca AB (SE) 2011-12-07 — — EP claimed
US-20110224273-A1 Pyrazole Derivatives as 11-Beta-HSD1 Inhibitors ASTRAZENECA AB (SE) 2011-09-15 — — US claimed
US-7951833-B2 Crystalline forms of 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]Benzoic acid 471 ASTRAZENECA AB (SE) 2011-05-31 — — US claimed
US-20110060022-A1 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]Benzoic Acid - 465 ASTRAZENECA AB (SE) 2011-03-10 — — US claimed
EP-2292228-A1 Pyrazole derivatives as 11-beta-HSD1 inhibitors AstraZeneca AB (Publ) (SE) 2011-03-09 — — EP claimed
US-20110028529-A1 NOVEL CRYSTALLINE FORMS OF 4-[4-(2-ADAMANTYLCARBAMOYL)-5-TERT-BUTYL-PYRAZOL-1-YL]BENZOIC ACID 471 ASTRAZENECA AB (SE) 2011-02-03 — — US claimed
US-20110028530-A1 NOVEL CRYSTALLINE FORMS OF 4-[4-(2-ADAMANTYLCARBAMOYL)-5-TERT-BUTYL-PYRAZOL-1-YL]BENZOIC ACID 471 ASTRAZENECA AB (SE) 2011-02-03 — — US claimed
EP-2244705-A1 NOVEL CRYSTALLINE FORMS OF 4- [4- (2-ADAMANTYLCARBAM0YL) -5-TERT-BUTYL-PYRAZOL-1-YL]BENZOIC ACID AstraZeneca AB (SE) 2010-11-03 — — EP claimed
US-7816391-B2 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid; hydroxysteroid reductase inhibitors; hydrolysis; metabolic syndromes ASTRAZENECA AB (SE) 2010-10-19 — — US claimed
EP-2217232-A1 4-[4-(2-ADAMANTYLCARBAMOYL)-5-TERT-BUTYL-PYRAZOL-1-YL]BENZOIC ACID - 465 AstraZeneca AB (SE) 2010-08-18 — — EP claimed
WO-2010087770-A1 NOVEL PROCESS FOR PREPARING CARBOXY-CONTAINING PYRAZOLEAMIDO COMPOUNDS 597 ASTRAZENECA AB (SE) 2010-08-05 — — WO claimed
EP-2124937-A1 PYRAZOLE DERIVATIVES AS 11-BETA-HSD1 INHIBITORS AstraZeneca AB (SE) 2009-12-02 — — EP claimed
US-20090221663-A1 PYRAZOLE DERIVATIVES AS 11-BETA-HSD1 INHIBITORS ASTRAZENECA AB (SE) 2009-09-03 — — US claimed
US-20090221660-A1 NOVEL CRYSTALLINE FORMS OF 4-[4-(2-ADAMANTYLCARBAMOYL)-5-TERT-BUTYL-PYRAZOL-1-YL]BENZOIC ACID 471 ASTRAZENECA AB (SE) 2009-09-03 — — US claimed
WO-2009098501-A1 NOVEL CRYSTALLINE FORMS OF 4- [4- (2-ADAMANTYLCARBAM0YL) -5-TERT-BUTYL-PYRAZOL-1-YL] BENZOIC ACID ASTRAZENECA AB (SE) 2009-08-13 — — WO claimed
WO-2009060232-A1 4-[4-(2-ADAMANTYLCARBAMOYL)-5-TERT-BUTYL-PYRAZOL-1-YL]BENZOIC ACID - 465 ASTRAZENECA AB (SE) 2009-05-14 — — WO claimed
WO-2008099145-A1 PYRAZOLE DERIVATIVES AS 11-BETA-HSD1 INHIBITORS ASTRAZENECA AB (SE) 2008-08-21 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110060022-A1 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]Benzoic Acid - 465 HSD11B1, HSD3B1, HSD17B1 HSD11B1 1/4885
US-20110224273-A1 Pyrazole Derivatives as 11-Beta-HSD1 Inhibitors HSD11B1, HSD3B1, HSD11B2 HSD11B1 1/4885
US-20090221660-A1 NOVEL CRYSTALLINE FORMS OF 4-[4-(2-ADAMANTYLCARBAMOYL)-5-TERT-BUTYL-PYRAZOL-1-YL]BENZOIC ACID 471 HSD11B1, SRD5A1, CYP4A11 HSD11B1 1/4885
US-20120041211-A1 NOVEL PROCESS FOR PREPARING CARBOXY-CONTAINING PYRAZOLEAMIDO COMPOUNDS 597 CYP3A7, CYP2C9, CYP2A7 HSD11B1 3393/4885
US-20110028530-A1 NOVEL CRYSTALLINE FORMS OF 4-[4-(2-ADAMANTYLCARBAMOYL)-5-TERT-BUTYL-PYRAZOL-1-YL]BENZOIC ACID 471 HSD11B1, SRD5A1, CYP4A11 HSD11B1 1/4885
US-20110028529-A1 NOVEL CRYSTALLINE FORMS OF 4-[4-(2-ADAMANTYLCARBAMOYL)-5-TERT-BUTYL-PYRAZOL-1-YL]BENZOIC ACID 471 HSD11B1, SRD5A1, CYP4A11 HSD11B1 1/4885
US-20090221663-A1 PYRAZOLE DERIVATIVES AS 11-BETA-HSD1 INHIBITORS HSD11B1, HSD3B1, HSD11B2 HSD11B1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.